Newsfeeds - Spark Newswire

1 minute read

Aegis Capital Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $26

Today, 3:50 AM

Aegis Capital analyst Nathan Weinstein initiates coverage on ATAI Life Sciences (NASDAQ:ATAI) with a Buy rating and announces Price Target of $26.

ATAI

5 minute read

58 Biggest Movers From Friday

By Lisa Levin

Today, 3:50 AM

Gainers CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.

ACRE

2 minute read

Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public

By Natan Ponieman

Today, 3:50 AM

Atai Life Sciences (NASDAQ: ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday.

ATAI

1 minute read

List Of Initial Public Offerings For Friday, Jun. 18, 2021

By Michael Horton

Today, 3:50 AM

AiHuiShou International (RERE) Century Therapeutics (IPSC) ATAI Life Sciences (ATAI) Jaws Juggernaut Acquisition (JUGGU) Tremor International (TRMR) Ambrx Biopharma (AMAM) Cyteir Therapeutics (CYT) Codex DNA

AMAM

3 minute read

IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings

By Chris Katje

Today, 3:50 AM

This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.

ABBV

1 minute read

Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation

By Vandana Singh

Today, 3:50 AM

Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering.

ATAI

Latest news

Aegis Capital Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $26

58 Biggest Movers From Friday

Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public

List Of Initial Public Offerings For Friday, Jun. 18, 2021

IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings

Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation